Abstract:OBJECTIVE:To investigate the predictive value of prostate-specific antigen (PSA) and Gleason sum for results of radionuclide bone scintigraphy in prostate cancer patients, in order to determine when to perform a radionuclide bone scintigraphy in Chinese patients with newly diagnosed prostate cancer. METHODS:We retrospectively reviewed the charts of 624 consecutive patients with a pathology diagnosis of prostate cancer hospitalized in Department of Urology, Peking University First Hospital between Jan. 1994 and Dec. 2005, and evaluated the relationships between results of bone scintigraphy and serum tPSA, and between bone scintigraphy and Gleason sum. The receiver operating characteristics (ROC) curves were analyzed to determine the cut-off values of tPSA and Gleason sum for predicting positive results of bone scintigraphy. RESULTS:In the study, 443 patients underwent both a radionuclide bone scan and a serum PSA test prior to treatment, of whom, 216 (48.8%) got positive results, and 338 also possessed the Gleason sum for pathological evaluation. The serum tPSA levels were significantly higher in patients with positive results of the bone scan ( median: 71.00 μg/L; range: 1.30-2 400.00 μg/L) than those with negative results ( median: 60.00 μg/L; range: 0.60-201.00 μg/L; rank P<0.001), and the Gleason sums were also significantly higher in positive-bone-scan patients than in negative-bone-scan patients (7.7±1.5 vs. 6.7±1.8, P<0.001). Linear regression analysis suggested significant positive correlation between the results of the bone scan and the two afore-mentioned parameters, respectively (lg[PSA]: r=0.933, B=0.352, P=0.001; Gleason sum: r=0.971, B=0.096, P<0.001). The incidence of a positive bone scan result was 9.0% in patients with tPSA<10 μg/L and 3.8% in patients with Gleason sum<5. When the indication for bone scan was established as tPSA>15 μg/L or Gleason sum≥7,its sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy for positive results were 97.5%, 24.7%, 54.4%, 91.5% and 60.0%, respectively. CONCLUSION:In patients with prostate cancer, their positive results of the bone scan are significantly positively correlated to their higher PSA levels and higher Gleason sums, respectively. Our analyses suggest that a patient with newly diagnosed prostate cancer would not need to undergo radionuclide bone scintigraphy when the PSA level is lower than 10 μg/L and Gleason sum is less than 5, and that a prostate cancer patient with tPSA>15 μ g/L or Gleason sum≥7 should take a bone scintigraphy.

Role of P504S and Gleason Scores in Prostate Cancer Patients with Bone Metastasis

Relationship between prostate specific antigen new parameters and Gleason score and clinical stage

Sites of Synchronous Distant Metastases and Prognosis in Prostate Cancer Patients with Bone Metastases at Initial Diagnosis: a Population-Based Study of 16,643 Patients.

Predictive Value of Prostate-Specific Antigen and Gleason Sum for Results of Radionuclide Bone Scintigraphy in Patients with Prostate Cancer

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Clinical Significance of PSA and ECT in Diagnosis of Prostate Cancer with Bone Metastasis

Clinical Analysis of Prostate Cancer with Bone Metastasis: A Report of 63 Cases

[Gleason Histologic Grading of Prostate Carcinoma in Relation to Serum PSA, PSA in Situ and Immunohistochemical Expression of 34 Beta E12 and P504S].

Prognosis of Prostate Cancer and Bone Metastasis Pattern of Patients: a SEER-based Study and a Local Hospital Based Study from China

Value of Tumor Marker Alpha-methylacyl-CoA Racemase in Diagnosis of Prostatic Diseases

Can bone scan be spared in asymptomatic prostate cancer patients at the initial stage of diagnosis?

Study on Diagnostic Value of P1NP and Β-Ctx in Bone Metastasis of Patients with Breast Cancer and the Correlation Between Them.

Predictive Significance of Bone Sialoprotein and Osteopontin for Bone Metastases in Respectable Non-Small Cell Lung Cancer: A Retrospective Study

Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer

Clinical features and prognostic factors for patients with bone metastases from prostate cancer.

Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers.

The Application of Radionuclide Bone Scintigraphy,Serum PSA and ALP Measurement in Diagnosis of Bone Metastasis in Prostate Cancer Patients

Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases

Correlation Study of Expression Levels of Prostate-Specific Membrane Antigen and Prostate-Specific Antigen with Gleason Score of Prostate Carcinoma

Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases

Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer